Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Galderma

< Previous 1 2 Next >
Galderma @ WCD 2023: Late-Breaking Phase III Results for Nemolizumab Monotherapy in Prurigo Nodularis Show a Significant Proportion of Itch-Free Patients by Week 4
From Galderma
Via Business Wire
WCD 2023: Galderma to Present Extensive Data Demonstrating Enduring Commitment to Delivering Innovative Solutions in Dermatology
From Galderma
Via Business Wire
Galderma Raises Approximately USD 1 Billion for Newly Issued Shares in a Private Placement Round
From Galderma
Via Business Wire
Augmented Reality: Patient Experience Trumps Misconceptions Around Injectables
From Galderma
Via Business Wire
AMWC 2023: Data From Sculptra® Cheek Wrinkle and Alluzience® Star Studies Reinforce Strength of Galderma’s Broad Aesthetic Portfolio
From Galderma
Via Business Wire
AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab’s Significant Impact on Prurigo Nodularis
From Galderma
Via Business Wire
Galderma Delivers Strong FY 2022 Growth Driven by Innovation and Commercial Performance
From Galderma
Via Business Wire
Galderma Announces the Launch of FACE by Galderma™ – a Game-Changing Augmented Reality Solution Helping Healthcare Professionals Grow Their Activity and Improve Patient Satisfaction
From Galderma
Via Business Wire
IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio
From Galderma
Via Business Wire
Galderma Announces Intention to Expand Manufacturing and Innovation Footprint in Asia-Pacific
From Galderma
Via Business Wire
Galderma Debuts The Sensitive Skincare Faculty, a Global Expert Group to Improve Understanding and Management of Sensitive Skin
From Galderma
Via Business Wire
GALDERMA Showcases Its Continued Commitment to Innovation in Dermatology With New Data to Be Presented at 2022 EADV Congress
From Galderma
Via Business Wire
Galderma Delivers Strong H1 2022 Results and Continued Innovation Across Its Leading Dermatology Portfolio
From Galderma
Via Business Wire
Galderma Announces Positive Data From Phase III Trial, Demonstrating Efficacy and Safety of nemolizumab in Patients with Prurigo Nodularis
From Galderma
Via Business Wire
Galderma Announces Positive Results in Two Phase III Studies for a Novel Liquid Formulation botulinumtoxinA (RelabotulinumtoxinA) for the Treatment of Glabellar Lines (frown) and Lateral Canthal Lines (crow’s Feet)
From Galderma
Via Business Wire
Galderma to Present New Findings From Innovative Product Portfolio at the 2022 VCS Annual Symposium
From Galderma
Via Business Wire
Galderma to Present Extensive New Clinical Data Across Its Portfolio of Neuromodulators, Fillers and Biostimulators at the IMCAS World Congress 2022
From Galderma
Via Business Wire
Galderma to Present New Clinical Data and High Patient Satisfaction Across Their Portfolio of Dermal Fillers, Collagen Biostimulators and Liquid Neuromodulators at AMWC 2022
From Galderma
Via Business Wire
Galderma to Highlight Latest Science and Innovation Across Its Product Portfolio at the 2022 AAD Annual Meeting
From Galderma
Via Business Wire
Taro to Acquire Alchemee From Galderma
From Galderma
Via Business Wire
Tickers TARO
Karen L. Ling joins Galderma’s Advisory Committee
From Galderma
Via Business Wire
Galderma Successfully Completes Acquisition of ALASTIN Skincare®
From Galderma
Via Business Wire
Maria Teresa Hilado to Join Galderma’s Advisory Committee
From Galderma
Via Business Wire
Galderma Announces New Data Demonstrating the Positive Anti-inflammatory Effect and Mode of Action of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis
From Galderma
Via Business Wire
Galderma to Acquire Award-winning ALASTIN Skincare® Enhancing Its Integrated Dermatology Platform to Continue Delivering the Best Experience to Patients
From Galderma
Via Business Wire
RESTYLANE®, the Original Stabilized Hyaluronic Acid Filler, Celebrates 25 Years of Unmatched Achievement
From Galderma
Via Business Wire
Galderma Presents New Nemolizumab Data at EADV Reinforcing Rapid Onset of Action and Consistent Relief of Symptoms for People With Prurigo Nodularis and Atopic Dermatitis
From Galderma
Via Business Wire
Galderma Announces Exclusive Agreement With Sofregen to Develop the Next Generation of Biostimulator Fillers Using Silk-Based Technology
From Galderma
Via Business Wire
Galderma to Present New Data From Leading Aesthetics Portfolio and Launch* RESTYLANE® EYELIGHT™ at AMWC 2021
From Galderma
Via Business Wire
Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States
From Galderma
Via Business Wire
Tickers SLGL
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.